Magaldrate

Identification

Name
Magaldrate
Accession Number
DB08938
Type
Small Molecule
Groups
Approved, Withdrawn
Description

Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.

Structure
Thumb
Synonyms
  • Aluminium magnesium hydroxide sulfate hydrate
  • Aluminum magnesium hydroxide sulfate hydrate
  • Aluminum magnesium hydroxide sulphate hydrate
  • Hydrate magnesium aluminate activated sulfate
  • Magaldrate
  • Magaldrato
  • Magaldratum
  • Magnesium aluminate hydrate
  • Monalium hydrate
External IDs
AY 5710 / AY-5710
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Riopan Chewable Tablets 480mgTablet480 mgOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada
Riopan Sus 480mg/5mlSuspension480 mgOralWhitehall Robins Inc.1993-12-312002-07-19Canada
Riopan Suspension 480mg/5mlSuspension480 mgOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada
Riopan Tab 480mgTablet480 mgOralWhitehall Robins Inc.1993-12-312002-07-19Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Riopan Plus SusMagaldrate (480 mg) + Dimethicone (20 mg)SuspensionOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada
Riopan Plus SuspensionMagaldrate (96 mg) + Dimethicone (4 mg)SuspensionOralWhitehall Robins Inc.1993-12-312001-07-26Canada
Riopan Plus TabletsMagaldrate (480 mg) + Dimethicone (20 mg)TabletOralWhitehall Robins Inc.1993-12-311998-07-29Canada
Zantanol Tab.Magaldrate (50 mg/424mg) + Magnesium oxide (50 mg/424mg)TabletOralCho-A Pharm.Co.,Ltd.2017-02-28Not applicableUs
International/Other Brands
Almadrat T (Actavis) / Almagel T (Balkanpharma) / Antashin (Standard) / Bemolan (Nycomed) / Cremag (Zuoz) / Glysan (Riemser) / Lowsium (Rugby) / Magacid (Purzer) / Malugastrin (Polfa Lódz) / Riopan (Nycomed) / Sanaflat (Perumed)
Categories
UNII
6V88E24N5T
CAS number
74978-16-8
Weight
Average: 1115.3
Monoisotopic: 1111.7570627
Chemical Formula
Al5H33Mg10O40S2
InChI Key
SPPNVMTVMQOKSC-UHFFFAOYSA-A
InChI
InChI=1S/5Al.10Mg.2H2O4S.32H2O/c;;;;;;;;;;;;;;;2*1-5(2,3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h;;;;;;;;;;;;;;;2*(H2,1,2,3,4);32*1H2/q5*+3;10*+2;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/p-35
IUPAC Name
pentaaluminium(3+) decamagnesium(2+) hydrate hentriacontahydroxide disulfate
SMILES
O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Aluminium oxide: absorbed Al ions are eliminated in the urine (0.1-0.5 mg of Al in aluminium-containing antacid is absorbed from standard daily doses of antacid) while insoluble or poorly absorbed Al salts in the intestines are excreted through the feces.

Magnesium oxide: absorbed Mg ions (up to 30%) are eliminated in the urine, unabsorbed is excreted in the feces.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidMagaldrate can cause a decrease in the absorption of 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
1alpha-Hydroxyvitamin D5The serum concentration of Magaldrate can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
2,5-Dimethoxy-4-ethylamphetamineMagaldrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.
2,5-Dimethoxy-4-ethylthioamphetamineMagaldrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.
3-Aza-2,3-Dihydrogeranyl DiphosphateMagaldrate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3,4-MethylenedioxyamphetamineMagaldrate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.
4-Bromo-2,5-dimethoxyamphetamineMagaldrate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.
AbafunginMagaldrate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcepromazineMagaldrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AceprometazineMagaldrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,923,660.

General References
  1. Kurtz W: [A layered lattice antacid with long-term effectiveness. Profile of action and safety exemplified by magaldrate]. Fortschr Med. 1993 Feb 28;111(6):93-6. [PubMed:8462913]
  2. Varas Lorenzo MJ, Lopez Martinez A, Gordillo Bernal J, Mundet Surroca J: [Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer]. Rev Esp Enferm Dig. 1991 Aug;80(2):91-4. [PubMed:1790087]
External Links
KEGG Drug
D04832
PubChem Compound
3086011
PubChem Substance
310264905
ChEMBL
CHEMBL3833350
Drugs.com
Drugs.com Drug Page
Wikipedia
Magaldrate
ATC Codes
A02AF01 — Magaldrate and antiflatulentsA02AD02 — Magaldrate
MSDS
Download (94.8 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionOral
TabletOral
SuspensionOral480 mg
TabletOral480 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 22, 2014 13:08 / Updated on December 16, 2018 06:54